Tildrakizumab: short-term efficacy and safety in real clinical practice

Int J Dermatol. 2022 Sep;61(9):e355-e357. doi: 10.1111/ijd.15840. Epub 2021 Oct 11.

Authors

Manuel Galán-Gutierrez¹, Lourdes Rodriguez-Fernandez Freire², Ricardo Ruiz-Villaverde³

Affiliations

¹ Dermatology Unit, Hospital Universitario Reina Sofia, IMIBIC. Universidad de Córdoba, Córdoba, Spain.
² Dermatology Unit, Hospital Universitario Virgen del Rocio, Sevilla, Spain.
³ Dermatology Unit, Hospital Universitario San Cecilio, Instituto de Investigación Biosanitaria ibs, Granada, Spain.

PMID: 34632570
DOI: 10.1111/ijd.15840

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized* / adverse effects
Humans
Psoriasis* / drug therapy
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
tildrakizumab